{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:13:54Z","timestamp":1791101634885,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.nmd.2006.03.005","type":"journal-article","created":{"date-parts":[[2006,5,5]],"date-time":"2006-05-05T02:30:33Z","timestamp":1146796233000},"page":"374-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["The gross motor function measure\u2122 is a valid and sensitive outcome measure for spinal muscular atrophy"],"prefix":"10.1016","volume":"16","author":[{"given":"Leslie","family":"Nelson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollis","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Hynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan T.","family":"Iannaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"AmSMART Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2006.03.005_bib1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ana.410410214","article-title":"Deletions and conversion in spinal muscular atrophy patients: is there a relationship to severity?","volume":"41","author":"DiDonato","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib2","article-title":"Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy","author":"Andreassi","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.nmd.2006.03.005_bib3","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1093\/hmg\/ddg256","article-title":"Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy","volume":"12","author":"Brichta","year":"2003","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2006.03.005_bib4","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/mus.10455","article-title":"Riluzole attenuates spinal muscular atrophy disease progression in a mouse model","volume":"28","author":"Haddad","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.03.005_bib5","first-page":"60","article-title":"A phase one trial of riluzole in spinal muscular atrophy","author":"Russman","year":"2003","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.nmd.2006.03.005_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/WNL.59.4.609","article-title":"Pilot trial of albuterol in spinal muscular atrophy","volume":"59","author":"Kinali","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2006.03.005_bib7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.20548","article-title":"Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells","volume":"58","author":"Grzeschik","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib8","unstructured":"Markowitz JA, Coovert DD, Schussler K, Burghes AHM, Fischbeck KH, Taylor JP. Valproic acid increases SMN levels in SMA fibroblasts, Sixth Annual International Spinal Muscular Atrophy Research Group Meeting, 2002;6:35."},{"key":"10.1016\/j.nmd.2006.03.005_bib9","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/hmg\/10.24.2841","article-title":"Aclarubicin treatment restores SMN levels to cells derived from type 1 spinal muscular atrophy patients","volume":"10","author":"Andreassi","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2006.03.005_bib10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ana.10743","article-title":"Valproic acid increases SMN levels in spinal muscular atrophy patient cells","volume":"54","author":"Sumner","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2003.11.006","article-title":"Pilot trial of phenylbutyrate in spinal muscular atrophy","volume":"14","author":"Mercuri","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2006.03.005_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archneur.60.8.1130","article-title":"Reliability of four outcome measures in pediatric spinal muscular atrophy","volume":"60","author":"Iannaccone","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1469-8749.1989.tb04003.x","article-title":"The gross motor function measure: a means to evaluate the effects of physical therapy","volume":"31","author":"Russell","year":"1989","journal-title":"Dev Med Chil Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib14","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ptj\/80.10.974","article-title":"Validation of a model of gross motor function for children with cerebral palsy","volume":"80","author":"Palisano","year":"2000","journal-title":"Phys Ther"},{"key":"10.1016\/j.nmd.2006.03.005_bib15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.288.11.1357","article-title":"Prognosis for gross motor function in cerebral palsy: creation of motor development curves","volume":"288","author":"Rosenbaum","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.nmd.2006.03.005_bib16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1469-8749.2002.tb00308.x","article-title":"Comparing reliability and validity of pediatric instruments for measuring health and well-being of children with spastic cerebral palsy","volume":"44","author":"McCarthy","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1191\/026921598673571117","article-title":"Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures","volume":"12","author":"Ketelaar","year":"1998","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.nmd.2006.03.005_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/ptj\/80.9.873","article-title":"Improved scaling of the gross motor function measure for children with cerebral palsy: evidence of reliability and validity","volume":"80","author":"Russell","year":"2000","journal-title":"Phys Ther"},{"key":"10.1016\/j.nmd.2006.03.005_bib19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/088307380201700407","article-title":"Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy","volume":"17","author":"Fattal-Valevski","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib20","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneur.59.9.1445","article-title":"Outcome measures for pediatric spinal muscular atrophy","volume":"59","author":"Iannaccone","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mus.880120302","article-title":"Relationship of manual muscle testing to objective strength measurements","volume":"12","author":"Aitkens","year":"1989","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.03.005_bib22","first-page":"175","article-title":"Clinical trials in spinal muscular atrophy: protocol development and reliability of quantitative strength assessment method","volume":"6","author":"Barker","year":"1992","journal-title":"J Neurol Rehabil"},{"key":"10.1016\/j.nmd.2006.03.005_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/mus.1070","article-title":"Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children","volume":"24","author":"Escolar","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2006.03.005_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1017\/S0317167100053397","article-title":"Quantitative motor assessment in myotonic dystrophy","volume":"30","author":"Mathieu","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.nmd.2006.03.005_bib25","first-page":"S88","article-title":"Randomized creatine trial in childhood spinal muscular atrophy","volume":"56","author":"Iannaccone","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2006.03.005_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(01)00632-3","article-title":"A placebo-controlled trial of gabapentin in spinal muscular atrophy","volume":"191","author":"Miller","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nmd.2006.03.005_bib27","unstructured":"American Psychological Association, 1985 ed. Standards for educational and psychological testing. Washington, DC: American Psychological Association: p 9 and 19."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896606000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:54:13Z","timestamp":1760774053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896606000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0960896606000915"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2006.03.005","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The gross motor function measure\u2122 is a valid and sensitive outcome measure for spinal muscular atrophy","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2006.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}